HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 231 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $394,491 | +16.5% | 10,327 | +10.0% | 0.01% | 0.0% |
Q2 2023 | $338,589 | -23.2% | 9,387 | -18.7% | 0.01% | -16.7% |
Q1 2023 | $440,827 | -32.7% | 11,543 | -22.4% | 0.01% | -53.8% |
Q2 2022 | $655,000 | -84.7% | 14,877 | -86.1% | 0.01% | -58.1% |
Q4 2021 | $4,289,000 | +160.4% | 106,663 | +194.2% | 0.03% | +106.7% |
Q2 2021 | $1,647,000 | +345.1% | 36,260 | +308.1% | 0.02% | +275.0% |
Q1 2021 | $370,000 | -5.6% | 8,886 | -40.5% | 0.00% | -50.0% |
Q3 2020 | $392,000 | +28.9% | 14,932 | -11.6% | 0.01% | -33.3% |
Q1 2020 | $304,000 | -80.4% | 16,890 | -80.7% | 0.01% | -57.1% |
Q4 2019 | $1,551,000 | +32.2% | 87,486 | +15.7% | 0.03% | -12.5% |
Q3 2019 | $1,173,000 | +33.1% | 75,611 | +47.5% | 0.03% | +28.0% |
Q2 2019 | $881,000 | +384.1% | 51,270 | +410.5% | 0.02% | +257.1% |
Q3 2018 | $182,000 | -30.8% | 10,044 | -51.0% | 0.01% | -73.1% |
Q2 2017 | $263,000 | +48.6% | 20,499 | +50.4% | 0.03% | +52.9% |
Q1 2017 | $177,000 | +10.6% | 13,633 | -15.8% | 0.02% | 0.0% |
Q2 2014 | $160,000 | – | 16,199 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |